Stem Cell Clinic

Cartilage Repair/ Cartilage Regeneration Market 2022 Size, Competitive Landscape and Key Regions 2030 This Is Ardee – This Is Ardee

By adminAugust 2, 2022Stem Cell Clinics

Global Cartilage Repair/ Cartilage Regeneration Market Size study, By Treatment Modality (Cell-based {Chondrocyte Transplantation, Stem Cells, Growth Factors}. Non-cell-based {Tissue Scaffolds, Cell-free Composites}), By Application (Hyaline Cartilage, Fibrocartilage), By Application Site (Knee, Hip, Ankle and Foot, Other Application Sites, By End User (Hospitals, Ambulatory Surgery Centers and Clinics), and Regional Forecasts 2022-2028

Global Cartilage Repair/ Cartilage Regeneration Market is valued approximately USD 787 Million in 2021 and is anticipated to grow with a healthy growth rate of more than 15.30% over the forecast period 2022-2028.

Download Free Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

Cartilage repair or cartilage regeneration is a treatment for the joint that are healthy but have damaged cartilage due to the injury-causing impaired function and pain. Articular cartilage injuries happen because of the obliteration of the cartilage such as traumatic injury, direct blow, and progressive degeneration. The growing incidence of bone and joint disorders, such as Osteoarthritis (OA) or arthritis, increasing obese and geriatric population, availability of research funding and investments, coupled with the technological development and advancements of innovative treatment approaches are the chief factors that may surge the market demand around the world. For instance, according to the Centers for Disease Control and Prevention (CDC), there were nearly 64 million US adults have several varieties of arthritis, a figure that is anticipated to rise 78 million by the year 2040. Also, it is expected to be above 100 types of arthritis, osteoarthritis (OA) is the most common type of arthritis, which is affecting 32.5 million US adults. Thereby, the rising prevalence of bone and joint disorders will propel the market demand in the impending years. However, the high cost of cartilage repair surgeries and several limitations of cartilage-based stem cell products impedes the growth of the market over the forecast period of 2022-2028. Also, an increasing number of technological advancements is anticipated to act as a catalyzing factor for the market demand during the forecast period.

The key regions considered for the global Cartilage Repair/ Cartilage Regeneration Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising prevalence of musculoskeletal diseases, increasing research investments in the US and Canada, and the presence of major market players in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the high burden of osteoarthritis, as well as the growing occurrence of sports injuries, would create lucrative growth prospects for the Cartilage Repair/ Cartilage Regeneration Market across the Asia-Pacific region.

SPECIAL OFFER (Avail an Up-to 30% discount on this report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

Major market players included in this report are: Orthocell Ltd. Braun Melsungen Ag Arthrex, Inc. DePuy Synthes Company Smith & Nephew plc Zimmer Biomet Company Conmed Corporation Stryker Corporation Regrow Biosciences Pvt. Ltd. Vericel Corporation The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

Access full Report Description, TOC, Table of Figure, Chart, etc :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

By Treatment Modality:Cell-based Chondrocyte Transplantation Stem Cells Growth Factors Non-cell-based Tissue Scaffolds Cell-free Composites By Application:Hyaline Cartilage Fibrocartilage By Application Site:Knee Hip Ankle and Foot Other Application Sites By End User:Hospitals Ambulatory Surgery Centers and Clinics By Region:North America U.S. Canada Europe UK Germany France Spain Italy ROE

Asia Pacific China India Japan Australia South Korea RoAPAC Latin America Brazil Mexico Rest of the World

Table of Content

Access Full Report, here:-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

About Report Ocean: We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us: Report Ocean: Email:sales@reportocean.com Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.reportocean.com/

See original here:
Cartilage Repair/ Cartilage Regeneration Market 2022 Size, Competitive Landscape and Key Regions 2030 This Is Ardee - This Is Ardee

Turning Back the Clock on ALS Cells Reveals New Mechanism – Technology Networks

By adminAugust 2, 2022Adult Stem Cells

At the current time, there is no cure for amyotrophic lateral sclerosis (ALS). Things may be about to change, however. Researchers at FAU and the University of California San Diego (UCSD) have identified a protein that already displays pathological characteristics at an early stage of the neurological disease. The team has published their discovery, that could lead to a new approach for treating the disease, in the journal Acta Neuropathologica.

In summer 2014, amyotrophic lateral sclerosis, or ALS for short, received a lot of attention through a social media campaign. In the ice bucket challenge, millions of people across the globe emptied a bucket of ice cold water over their heads to simulate a feeling of paralysis due to the extreme cold. In Germany, approximately 6,000 to 8,000 people are living with ALS, and approximately 2,000 new cases of the disease, that proves fatal within just a few years, are diagnosed every year. ALS is a motor neuron disease, that means it damages the nerve cells that control our muscles, explains Prof. Dr. Beate Winner. During the first phase, muscles become weaker, before wasting away and finally leaving patients unable to swallow or breathe independently. The social media campaign was used to raise money for research into ALS.

Beate Winner is a professor for stem cell models for rare neural diseases at FAU, head of the Department of Stem Cell Biology, and speaker for the Center for Rate Diseases at Universittsklinikum Erlangen. Her laboratory investigates what triggers neurodegenerative diseases of the nervous system such as ALS in the hope of discovering new treatment options as a result. We have known for roughly 15 years that during the end stage of ALS, the protein TDP-43 found in neurons becomes insoluble and starts to form clumps, explains Winner. It loses its normal functions and adopts toxic properties. Even though these pathological changes are not yet noticeable in patients, the fate of the nerve cells is already sealed. Winner continues, We wanted to know whether we could find causes for ALS at an early stage of development before the TDP-43 changes.

She started her quest together with Prof. Dr. Jrgen Winkler and PD Dr. Martin Regensburger from the Department of Molecular Neurology at Universittsklinikum Erlangen. The researchers used an innovative technique. They extracted a small skin sample from the upper arm of ALS patients and healthy people in a control group and reprogrammed it into what are known as induced pluripotent stem cells, cells that are equivalent to a very early stage of human development and that can in theory develop into any cell within the human body. These stem cells were then transformed into nerve cells. Basically, we turned the clock back and generated neurons imitating the developmental stage of a fetus, explains Winner. The fact that cells from adult people can be reprogrammed back into pluripotent stem cells was discovered by Shinya Yamanaka, who received the Nobel Prize for Medicine in recognition of his work.

The Erlangen researchers searched for insoluble proteins in the cell samples using mass spectrometry, a high-throughput procedure. They were successful. In the nerve cells of ALS patients they discovered an RNA-binding protein named NOVA1. In the neurons, the protein demonstrated changes including a greatly increased degree of insolvency, but not yet the typical pathological characteristics of TDP-43, explains Dr. Florian Krach, member of the FAU team and lead author of the study. The cells in the control group did not display these changes.

Armed with these findings, Krach moved to the laboratory of the renowned RNA biologist and bioinformatics specialist Prof. Gene Yeo at the University of California in San Diego (USA), funded by the Bavaria California Technology Center (BaCaTeC). Thanks to specialized experiments and computer-assisted analysis he was able to investigate what NOVA1 binds to in RNA molecules and what influence it has on alternative splicing in human neurons. Alternative splicing is an extremely complex and ingenious mechanism that humans use to multiply their repertoire of proteins, explains Krach. Sections of an RNA messenger molecule are either cut or added, thereby hindering, extending or changing the function of proteins altogether.

It has been known for some time that the alternative splicing process is unregulated in ALS patients. It is also known that TDP-43 influences this process. The team of researchers from Erlangen suspected, however, that other RNA-binding proteins are responsible for the pathological processes in early stages of the disease before TDP-43 changes. This suspicion has now been confirmed with the discovery of the impaired functioning of NOVA1.

We have made a pioneering discovery, but it is only one first step towards possibly being able to detect ALS in the early stages, says Beate Winner. Follow-up studies with larger cohorts could deepen our understanding of the importance of RNA-binding proteins. The researchers hope that their work will help contribute to developing new therapy concepts before neurons cross the point of no return.

Reference:Krach F, Wheeler EC, Regensburger M, et al. Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis. Acta Neuropathol. 2022. doi:10.1007/s00401-022-02450-3

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the rest here:
Turning Back the Clock on ALS Cells Reveals New Mechanism - Technology Networks

Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News – University of Hawaii

By adminAugust 2, 2022Adult Stem Cells

Stephanie Si Lim

A therapy that helps modify a patients T cells (a type of immune cell) to make them more capable of fighting cancer was recently brought to Hawaii by Stephanie Si Lim, assistant professor at the University of Hawaii Cancer Center and pediatric hematologist oncologist at Kapiolani Medical Center for Women & Children. Chimeric Antigen Receptor T-cell therapy (CAR T-cell therapy) can result in the development of life-saving treatments for cancers that are difficult to treat.

Si Lim is leading the initiative at Kapiolani Medical Center for Women & Childrenpart of Hawaii Pacific Healthto build a broader cellular immunotherapy program. A key goal of the program is to introduce CAR T-cell therapy to the medical community in Hawaii in the form of clinical trials and U.S. FDA (Food and Drug Administration) approved products. This will ensure that patients have access to the best available treatments for cancer.

CAR T-cell therapy is now available to children and young adults with non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia, and will soon be available to adult patients.

The first CAR T-cell clinical trial opened on May 14, 2022, at Kapiolani Medical Center for Women & Children, leveraging the infrastructure and expertise of the hospitals stem cell transplant and clinical research programs. Moving forward, all patients living in Hawaii, including the neighbor islands who qualify for this clinical trial, will be able to receive treatment on Oahu without having to travel to the continental U.S.

Si Lim said, We are so excited to be able to offer CAR T-cell therapy to our patients here in Hawaii. This is a momentous step for our medical community as we continue to strive to offer the best and most cutting-edge therapies to patients in need.

Currently, CAR T-cell therapy is proven to be particularly effective against B-cell malignancies and multiple myelomaboth common forms of cancer in adults and pediatric populations in Hawaii. Over the next few years, it is expected that new FDA-approved CAR T-cell treatments will also be available for other cancers in the state, including breast and prostate.

The rest is here:
Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News - University of Hawaii

The amniotic products market is expected to grow from US$ – GlobeNewswire

By adminJuly 25, 2022Stell Cell Research

New York, July 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Amniotic Products Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, End User, and Geography" - https://www.reportlinker.com/p06295644/?utm_source=GNW The amniotic membrane and suspension are two products that can be used for treatment.

The amniotic membrane is the innermost layer of the placenta that nourishes and maintains an unborn child. Amniotic fluid is the liquid that surrounds the baby until delivery. Due to the high prevalence of burn wounds, demand for wound care biologics, such as amniotic membranes, has increased significantly.According to the WHO, many burn cases occur in low- and middle-income countries, with over 2-3rd occurring in the WHO African and Southeast Asian areas.

Every year, one million people in India suffer from mild to severe burns (Source: WHO).Other Southeast Asian countries, such as Bangladesh and Nepal, have a high rate of burn cases.

An estimated 173,000 children in Bangladesh yearly suffer from moderate to severe burns. Burn is Nepals second most prevalent injury, accounting for 5% of disability cases. Based on type, the amniotic products market has been bifurcated into amniotic membranes and amniotic suspensions.The amniotic membranes segment is likely to hold the largest share of the market in 2022.

The amniotic membrane segment growth is growing due to increasing research in stem cell and regenerative medicine, high R&D investments, and an increase in the number of surgeries conducted globally.Further, they are commonly employed in the treatment of bacterial keratitis, corneal ulcers, cataract, glaucoma, bullous keratopathy, corneal degeneration, ocular dystrophy, eyelid reconstruction, and other eye surface problems.

The expansion in the worlds senior population increases the number of ophthalmology surgeries, , resulting in a growing need for tissue-based products.Further, PalinGen, Fl?Graft, AmbioDisk, and AmnioFix are examples of commercially available dehydrated amniotic membranes.

In addition, these membranes are widely used in the treatment and management of surgical wounds and incisions, owing to properties such as their ability to maintain a watertight seal, inhibit inflammatory responses, and prevent disease transmissions. Hence, these factors are driving the segment growth. In December 2016, the US passed the 21st Century Cures Act.This new law was passed with the goal of advancing regenerative medicine research and medical innovation.

The Act contains a number of provisions that could impact the development and approval of many products in the coming years.A new "Regenerative Medicine Advanced Therapy" classification and a fast-track approval procedure for innovative regenerative medicine products and therapies have been developed due to this Act.

The passage of this Act could lead to the approval of new regenerative medicine products and therapies in the US and a boost in regenerative medicine research and development.It was designed to promote patient access to electronic health information, advance innovation, and address information blocking practices.

The 21st Century Cures Act was created to help speed up medication development and approval processes, allowing for faster and more efficient delivery of new medical advancements to patients. These requirements are expected to improve interoperability and facilitate electronic health information access, exchange, and use. A few key primary and secondary sources referred to while preparing the report on the prostate cancer nuclear medicine diagnostics market are the World Health Organization (WHO), the Centers for Disease Control and Prevention, and the National Programme for Prevention, Management and Rehabilitation of Burn Injuries. Read the full report: https://www.reportlinker.com/p06295644/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post:
The amniotic products market is expected to grow from US$ - GlobeNewswire

Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans – VegNews

By adminJuly 25, 2022Stell Cell Research

Cell-cultured seafood startup Pearlita Foods has successfully created the worlds first plant-based oyster prototype that looks and tastes just like a traditional oyster. The prototype is made using plant-based and cell-based technologies with a proprietary mushroom and seaweed base as well as Pearlitas novel flavor mixture that gives the oyster a pure, delicate, and authentic ocean taste and texture. The startup also plans to create biodegradable oyster shells that will impart the same experience as traditional oysters but remove the need for shucking, making it easier for consumers to serve and eat.

Earlier this year, Pearlita embarked on producing an alternative to oysters in an effort to meet the demand for ocean-derived delicacies using plant-based and cell-based technologies without harming the oceans. The startup will begin by rolling out its hybrid product while it continues to develop its cell lines for a line of fully cultured oysters. To cultivate oysters, Pearlita isolates cells from an oyster tissue sample, and with it, the startup is able to produce thousands of cultivated oysters.

While the startup continues its research and development on cultured oysters and biodegradable shells, Pearlita will debut its hybrid plant-based oyster using recycled oyster shells for its showcasing and tastings. In North Carolina, where Pearlita is headquartered, many coastal communities offer shell recycling drop-off locations to build new oyster reefs instead of disposing of the shells in landfills.

Pearlita Foods

According to Pearlita, over 85 percent of wild oyster reefs have been lost globally due to overfishing. Pearlita wants to change the seafood industry and it is striving to make cultivated oysters and other cell-based seafood commonplace so that traditional oysters can remain in the oceans and contribute to healthy ecosystems. Additionally, according to government advisories from the Centers for Disease Control and Prevention, ocean-derived bivalve shellfish such as clams, geoducks, mussels, scallops, and oysters can transmit norovirus to the people who eat them. These illness outbreaks are most often linked to oysters and can be deadly.

The startup aims to produce oysters with no reliance on the ocean or live animals, by using stem cells and bioreactors to produce cell-based oysters that are rich in flavor and nutrition. And because they are produced in a sterile environment, cultivated seafood is devoid of bacteria and virus contamination. Going forward, Pearlita plans to develop squid and scallop prototypes as well and work on scaling up production.

The cellular aquaculture startup recently secured investment from investment firm CULT Food Science to help scale its prototype. We are impressed by and proud of Pearlitas successful production of its first cultivated oyster prototype. Pearlitas commitment to making the world a better place and doing its part to increasing the worlds food security is encouraging as we possess the same goals, Lejjy Gafour, Chief Executive Officer of CULT, said in a statement. Pearlita is taking great steps to advance the production of cultured seafood on a mass scale. We are energized by the positive contributions that their team is making to the cellular agriculture industry.

Finless Foods

While Pearlita is focusing on developing ethical and sustainable seafood alternatives to ocean delicacies such as oysters, other food technology companies are tackling fish species such as tunawhich is the most consumed fish in the United States. Finless Foods is taking a similar approach to Pearlita by using plants and cultivated cells to make sustainable seafood, starting with tuna which will be available to restaurants and foodservice channels this year.

Earlier this year, Finless Foods showcased its plant-based tuna as part of a poke bowl and tacos served to guests at the Food Network & Cooking Channel South Beach Wine & Food Festival in Miami. The product is made from a blend of nine proprietary, plant-based ingredients that together mimic the texture and taste of sushi-grade tuna while also being able to withstand the addition of citrus and marinades.

Tuna plays an important role in ocean health and has historically been a difficult species for aquaculture, Finless Foods co-founder Brian Wyrwas said in a statement. We felt that developing viable alternatives would yield the greatest net impact for our ocean.

Other competitors in the cellular aquaculture space include San Diego-based BlueNalu, which is working to develop cell-based alternatives to fish, including yellowtail amberjack which it sampled in a private-tasting in 2019. In San Francisco, cellular aquaculture startup Wild Type is also working on growing sushi-grade meat made from a small amount of fish cells. Its pilot facility became operational in 2021 and Wild Type hopes to open an adjacent tasting restaurant where its cultivated fish can be showcased in traditional (but more sustainable) sushi preparations.

Over in Singapore, the countrys first cell-based seafood startup, Shiok Meats, is creating cultivated crab and lobster. Currently, Singapore is the only country in the world that allows the sale of cultivated meat. There, cultivated chicken made by GOOD Meat (a subsidiary of Eat Just) was approved for sale in December 2020.

For the latest vegan news, read: Chipotle Invested a $150 Million Funding Round For Vegan Steak StartupNavy Will Test Vegan Meat on at Least 2 US BasesCountry Crocks First Whipping Cream Is Made From Lentil Milk

Nicole Axworthy is the News Editor at VegNews and author of the cookbook DIY Vegan.

Happy birthday, VegNews! To celebrate, we're having a mega subscription salecomplete with incredible vegan prizes.

CHECK IT OUT

Happy birthday, VegNews! To celebrate, we're having a mega subscription salecomplete with incredible vegan prizes.

CHECK IT OUT

University of Minnesota scientist responds to fraud allegations in Alzheimer’s research – Star Tribune

By adminJuly 25, 2022Stell Cell Research

A senior University of Minnesota scientist said it is "devastating" that a colleague might have doctored images to prop up research, but she defended the authenticity of her groundbreaking work on the origins of Alzheimer's disease.

Dr. Karen Ashe declined to comment about a U investigation into the veracity of studies led by Sylvain Lesn, a neuroscientist she hired and a rising star in the field of Alzheimer's research. However, she criticized an article in Science magazine that raised concerns this week about Lesn, because she said it confused and exaggerated the effect the U's work had on downstream drug development to treat Alzheimer's-related dementia.

"Having worked for decades to understand the cause of Alzheimer disease, so that better treatments can be found for patients, it is devastating to discover that a co-worker may have misled me and the scientific community through the doctoring of images," Ashe said in an e-mail Friday morning. "It is, however, additionally distressing to find that a major scientific journal has flagrantly misrepresented the implications of my work."

Questions have surfaced about as many as 10 papers written by Lesn, and often coauthored by Ashe and other U scientists, and whether they used manipulated or duplicated images to inflate the role of a protein in the onset of Alzheimer's.

The Science article detailed efforts by Dr. Matthew Schrag, an Alzheimer's researcher in Tennessee, who colorized and magnified images from Lesn's studies in ways that revealed questions about whether they were doctored or copied. Expert consultants agreed in the article that some of the images in the U studies appeared manipulated in ways that elevated the importance of a protein called A*56.

Many of the images were of Western blot tests showing that A*56, also called amyloid beta star 56, was more prevalent in mice that were older and showed signs of memory loss.

The U studies have been so influential on the course of Alzheimer's research over the past two decades that any evidence of manipulation or false study results could fundamentally shift thinking on the causes of the disease and dementia. The investigation also implicates two successful researchers on a key measure by which they are judged: their ability to pull in federal grants.

Lesn was a named recipient of $774,000 in National Institutes of Health grants specifically involving A*56 from 2008 through 2012. He subsequently received more than $7 million in additional NIH grants related to the origins of Alzheimer's.

Lesn, who did not reply to an e-mail asking for comment, came to the U in 2002 as a postdoctoral research associate after earning his doctorate at the University of Caen Normandy. He took charge of his own U lab by 2009 and became associate director of graduate studies in the neuroscience program in 2020. He was the first- or last-named author on all of the disputed studies, meaning he either instigated the research or was the senior scientist overseeing the work.

Ashe said there are two classes of A proteins, which she refers to as Abeta, and that her efforts have focused on one while drugmakers have unsuccessfully targeted the other with potential Alzheimer's treatments. As a result, she said it was unfair of the Science article even as it raised concerns about research improprieties to pin an entire industry's lack of progress on the scrutinized U research.

"It is this latter form that drug developers have repeatedly but unsuccessfully targeted," she said. "There have been no clinical trials targeting the type 1 form of Abeta, the form which my research has suggested is more relevant to dementia. [The article] has erroneously conflated the two forms of Abeta."

The scientific journal Nature is reviewing a 2006 study led by Lesn regarding the existence and role of A*56 and urging people to use it cautiously for now. Concerns emerged in part because researchers at other institutions struggled to replicate the results.

Two other 2012 and 2013 papers were corrected earlier this year, with U researchers acknowledging errant images but stating that they didn't affect the overall conclusions. However, Schrag said he has concerns the corrected images also were manipulated.

"I think those corrected images are quite problematic," he said.

Beneath the research controversy is a fundamental search and debate over the causes of Alzheimer's and related dementia. One theory is that certain Abeta proteins result in the development of amyloid plaques, which clog up space between nerve cells in the brain and inhibit memory and cognition. Another is that tau proteins clump inside the brain's thinking cells and disrupt them.

Ashe's research has explored both possibilities. Since 1986, she has been a named recipient of more than $28 million in NIH grants, making her one of the most productive researchers in U history.

Complicated legacy

Despite a remarkable history of life-saving inventions and surgical accomplishments, the U also has a legacy of research stars being implicated in scandals.

The late Dr. S. Charles Schulz stepped down as U psychiatry chair in 2015 amid claims by a grieving family that their son, who died by suicide, was coercively recruited into a schizophrenia drug trial.

Duplicated images and errors forced the correction of a 2002 Nature study, led by Dr. Catherine Verfaillie, claiming that certain adult stem cells possessed flexible abilities to grow and develop other cell types.

The late Dr. John Najarian was a pioneer in organ transplantation who elevated the U's global profile, but he faced federal sanctions in the 1990s related to illicit sales of an experimental anti-rejection medication that improved transplant outcomes.

A U investigation of Lesn's work will follow its standard policy of research misconduct allegations, according to a statement from the medical school.

Originally posted here:
University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune

Global Virus Filtration Market To Be Driven By The Increasing Incidence Of Chronic Diseases In The Forecast Period Of 2021-2026 This Is Ardee – This…

By adminJuly 25, 2022Stell Cell Research

The new report by Expert Market Research titled, GlobalVirus Filtration MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global virus filtration market, assessing the market based on its segments like product, applications, end-use, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://bityl.co/CQEk

The key highlights of the report include:

Market Overview (2016-2026)

One of the major factors driving to the virus filtration is the rising prevalence of chronic diseases. The increasing number ofchronicdiseases such ascancer,diabetes, and autoimmune disorders is expected to drivebiologicsdemand. The major driver, which is anticipated to increase the market growth during the forecast period, is the compliance of the product with drug development and manufacturing regulatory frameworks such as the Current Good Manufacturing Practice (cGMP) legislation. The increased focus on vaccines,proteintreatments, blood products, cellular therapy products, gene therapy products, tissue products, and stem cell products is likely to stimulate demand for consumables such as reagents, kits, and membranes. Increased demand for outsourcing services that cater to the specialised demands of vaccine and therapeutic protein manufacturing companies has come from a surge in the number of vaccine and therapeutic protein manufacturing companies, providing lucrative growth potential for the industry.

Industry Definition and Major Segments

Viruses are characterised as unwanted tiny contagious agents or particles that must be eradicated in order to prevent drug infertility, especially in the pharmaceutical sector. Virus filtration membranes are used to remove viruses from biopharmaceutical products during purification. It is a critical practice in the pharmaceutical sector because it ensures the purity and consistent consumption of vital products while also optimising the economic process and reducing waste. Virus filtering is usually done at the end of any process purification stage.

Explore the full report with the table of contents@https://bityl.co/CQEl

By product, the market includes:

The end use of the industry is divided into:

The leading application of the industry includes:

On the basis of region, the industry is divided into:

Market Trends

The demand for medicinal biologics is increasing, which drives up the demand for virus filtration products in research and development and manufacturing. CROs are cooperating with biotechnology and biopharmaceutical businesses to create new medications and therapies, which is projected to drive the market expansion. The increased usage of these products for virus filtration provides lucrative growth opportunities to the market. Product advancements and new product launches support vendors in maintaining their dominance in the market, which is anticipated to boost the market growth. The presence of big biopharmaceutical and biotechnology companies, well-developed healthcare infrastructure, and access to advanced products are some of the major factors contributing to growth of the marker. The increasing adoption of single-use technologies, coupled with rapid technological advancement, is anticipated to propel the market growth during the forecast period.

Key Market Players

The major players in the market are Merck Group, Asahi Kasei Corporation, Sartorius Group, General Electric, Danaher Corporation, Pendotech, Lonza Group, and Charles River Laboratories, Inc, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact

Company Name: Claight Corporation Contact Person: Steven Luke, Corporate Sales Specialist U.S.A. Email:sales@expertmarketresearch.com Toll Free Number: +1-415-325-5166 | +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA Website:https://www.expertmarketresearch.com

Global Stem Cell Banking Market To Be Driven At A CAGR Of 13.5% In The Forecast Period Of 2021-2026 This Is Ardee – This Is Ardee

By adminJuly 25, 2022Stem Cell Medicine

The new report by Expert Market Research titled, Global Stem Cell Banking Market Report and Forecast 2021-2026, gives an in-depth analysis of the globalstem cell banking market, assessing the market based on its segments like Service type, product type, utilisation, bank type, application, and major regions like Asia Pacific, Europe, North America, Middle East and Africa and Latin America. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://bityl.co/CPix

The key highlights of the report include:

Market Overview (2021-2026)

The global stem cell bank market is primarily driven by the advancements in the field of medicine and the rising prevalence of genetic and degenerativediseases. Further, the increasing research and development of more effective technologies for better preservation, processing, and storage of stem cells are aiding the growth. Additionally, rising prevalence of chronic diseases globally is increasing the for advances inmedicaltechnologies, thus pushing the growth further. Moreover, factors such as rising health awareness, developinghealthcare infrastructure, growing geriatric population, and the inflatingdisposableincomes are expected to propel the market in the forecast period.

Industry Definition and Major Segments

Stem cells are undifferentiated cells present in bone marrow,umbilical cordadipose tissue and blood. They have the ability to of differentiate and regenerate. The process of storing and preserving these cells for various application such as gene therapy, regenerative medicine and tissue engineering is known as stem cell banking.

Explore the full report with the table of contents@https://bityl.co/CPiy

By service type, the market is divided into:

Based on product type, the industry can be segmented into:

The market is bifurcated based on utilization into:

By bank type, the industry can be broadly categorized into:

Based on application, the industry can be segmented into:

On the basis of regional markets, the industry is divided into:

1 North America 1.1 United States of America 1.2 Canada 2 Europe 2.1 Germany 2.2 United Kingdom 2.3 France 2.4 Italy 2.5 Others 3 Asia Pacific 3.1 China 3.2 Japan 3.3 India 3.4 ASEAN 3.5 Others 4 Latin America 4.1 Brazil 4.2 Argentina 4.3 Mexico 4.4 Others 5 Middle East & Africa 5.1 Saudi Arabia 5.2 United Arab Emirates 5.3 Nigeria 5.4 South Africa 5.5 Others

Market Trends

Regionally, North America is projected to dominate the global stem cell bank market and expand at a significant rate. This can be attributed to increasing research and development for stem cell application in various medical fields. Further, growing investments of pharmaceutical players and development infrastructure are other factors that are expected to stem cell bank market in the region. Meanwhile, Asia Pacific market is also expected to witness fast growth owing to the rapid development in healthcare facilities and increasing awareness of stem cell banking in countries such as China, India, and Indonesia.

Key Market Players

The major players in the market are Cryo-Cell International, Inc., Smart Cells International Ltd., CSG-BIO Company, Inc., CBR Systems Inc., ViaCord, LLC, LifeCell International Pvt. Ltd., and a few others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Media Contact

How effective is stem cell therapy for liver cirrhosis? – Times of India

By adminJuly 25, 2022Stem Cell Treatment

Lifestyle diseases are gradually moving up the ranks causing deaths globally. Liver diseases appear to be one such condition, with a significantly increased number of patients being diagnosed each year. According to the WHO data published in 2017, liver disease was responsible for around 2.95% of the total deaths in India, accounting for one-fifth of all cirrhosis-associated deaths globally. Earlier, infections such as hepatitis B and C were the main causes; however, alcohol consumption and obesity are now becoming bigger contributors to liver disease. We know that the liver is responsible for detoxifying alcohol and drugs, but also performs multiple other functions, including glucose supply to the brain, food digestion, producing blood during foetal development, storing nutrients, etc. We also know that the liver can regenerate, but that does not mean a fully damaged liver can grow back on its own. Therefore, it is important to pay attention to signs of liver disease and initiate treatments promptly. Liver cirrhosis Cirrhosis is a condition where scars form in the liver causing the normal liver tissue to harden, thereby preventing the effective functioning of the organ. Cirrhosis and liver cancer are the prime causes of death due to liver disease globally. Regenerative medicine researcher Dr Pradeep Mahajan shares that alcohol consumption, viral hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, and several inherited metabolic disorders can cause cirrhosis. The disease process begins as inflammation (swelling) in the liver tissue followed by scar formation and ultimately liver failure. Considering that there is no cure for cirrhosis per se, symptom and lifestyle management remain the mainstay of conventional treatment. Liver transplantation is the only curative option for severe cases; however, the issue of organ shortage is a chief and ever-growing concern. How can one get treated? Dr Mahajan says: Since we know that the liver can regenerate itself, the way ahead is to diagnose the liver disease as early as possible and find ways to enhance its regenerative potential. This is where cell and growth factor-based therapy can be beneficial. Stem cells in our body are capable of differentiating into liver (and various other) cells. In addition, they are also capable of regulating the immune system, reducing inflammation, enhancing blood supply, and stimulating other cells to perform their functions more efficiently. Similarly, growth factors can be isolated from blood/platelets, which serve as nutrition for cells of the body. These can help in cirrhosis by stabilising the internal environment of the liver making it more conducive to healing and regeneration. We are simply trying to find ways to capitalise on the healing potential of the liver before issues like scarring happen. Of course, lifestyle modification will be required to enhance the outcomes, but the end goal is to prevent the need for (or at least delay) liver transplantation, which can significantly affect a patients quality of life, adds Dr Mahajan.

Read the original:
How effective is stem cell therapy for liver cirrhosis? - Times of India

Kite’s CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) – Gilead Sciences

By adminJuly 25, 2022Stem Cell Treatment

Tecartus (Brexucabtagene Autoleucel) First and Only CAR T in Europe to Receive Positive CHMP Opinion to Treat Adults 26+ with r/r ALL

If Approved, it will Address a Significant Unmet Need for a Patient Population with Limited Treatment Options

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL). If approved, Tecartus will be the first and only Chimeric Antigen Receptor (CAR) T-cell therapy for this population of patients who have limited treatment options. Half of adults with ALL will relapse, and median overall survival (OS) for this group is only approximately eight months with current standard-of-care treatments.

Kites goal is clear: to bring the hope of survival to more patients with cancer around the world through cell therapy, said Christi Shaw, CEO, Kite. Todays CHMP positive opinion in adult ALL brings us a step closer to delivering on the promise that cell therapies have to transform the way cancer is treated.

Following this positive opinion, the European Commission will now review the CHMP opinion; the final decision on the Marketing Authorization is expected in the coming months.

Adults with relapsed or refractory ALL often undergo multiple treatments including chemotherapy, targeted therapy and stem cell transplant, creating a significant burden on a patients quality of life, said Max S. Topp, MD, professor and head of Hematology, University Hospital of Wuerzburg, Germany. If approved, patients in Europe will have a meaningful advancement in treatment. Tecartus has demonstrated durable responses, suggesting the potential for long-term remission and a new approach to care.

Results from the ZUMA-3 international multicenter, single-arm, open-label, registrational Phase 1/2 study of adult patients (18 years old) with relapsed or refractory ALL, demonstrated that 71% of the evaluable patients (n=55) achieved complete remission (CR) or CR with incomplete hematological recovery (CRi) with a median follow-up of 26.8 months. In an extended data set of all patients dosed with the pivotal dose (n=78) the median overall survival for all patients was more than two years (25.4 months) and almost four years (47 months) for responders (patients who achieved CR or CRi). Among efficacy-evaluable patients, median duration of remission (DOR) was 18.6 months. Among the patients treated with Tecartus at the target dose (n=100), Grade 3 or higher cytokine release syndrome (CRS) and neurologic events occurred in 25% and 32% of patients, respectively, and were generally well-managed.

About ZUMA-3

ZUMA-3 is an ongoing international multicenter (US, Canada, EU), single arm, open label, registrational Phase 1/2 study of Tecartus in adult patients (18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. The primary endpoint is the rate of overall complete remission or complete remission with incomplete hematological recovery by central assessment. Duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate, and allo-SCT rate were assessed as secondary endpoints.

About Acute Lymphoblastic Leukemia

ALL is an aggressive type of blood cancer that develops when abnormal white blood cells accumulate in the bone marrow until there isnt any room left for blood cells to form. In some cases, these abnormal cells invade healthy organs and can also involve the lymph nodes, spleen, liver, central nervous system and other organs. The most common form is B cell precursor ALL. Globally, approximately 64,000 people are diagnosed with ALL each year, including around 3,300 people in Europe.

About Tecartus

Please see full FDA Prescribing Information, including BOXED WARNING and Medication Guide.

Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

U.S. IMPORTANT SAFETY INFORMATION

BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES

Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred following treatment with Tecartus. In ZUMA-2, CRS occurred in 91% (75/82) of patients receiving Tecartus, including Grade 3 CRS in 18% of patients. Among the patients who died after receiving Tecartus, one had a fatal CRS event. The median time to onset of CRS was three days (range: 1 to 13 days) and the median duration of CRS was ten days (range: 1 to 50 days). Among patients with CRS, the key manifestations (>10%) were similar in MCL and ALL and included fever (93%), hypotension (62%), tachycardia (59%), chills (32%), hypoxia (31%), headache (21%), fatigue (20%), and nausea (13%). Serious events associated with CRS included hypotension, fever, hypoxia, tachycardia, and dyspnea.

Ensure that a minimum of two doses of tocilizumab are available for each patient prior to infusion of Tecartus. Following infusion, monitor patients for signs and symptoms of CRS daily for at least seven days for patients with MCL and at least 14 days for patients with ALL at the certified healthcare facility, and for four weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.

Neurologic Events, including those that were fatal or life-threatening, occurred following treatment with Tecartus. Neurologic events occurred in 81% (66/82) of patients with MCL, including Grade 3 in 37% of patients. The median time to onset for neurologic events was six days (range: 1 to 32 days) with a median duration of 21 days (range: 2 to 454 days) in patients with MCL. Neurologic events occurred in 87% (68/78) of patients with ALL, including Grade 3 in 35% of patients. The median time to onset for neurologic events was seven days (range: 1 to 51 days) with a median duration of 15 days (range: 1 to 397 days) in patients with ALL. For patients with MCL, 54 (66%) patients experienced CRS before the onset of neurological events. Five (6%) patients did not experience CRS with neurologic events and eight patients (10%) developed neurological events after the resolution of CRS. Neurologic events resolved for 119 out of 134 (89%) patients treated with Tecartus. Nine patients (three patients with MCL and six patients with ALL) had ongoing neurologic events at the time of death. For patients with ALL, neurologic events occurred before, during, and after CRS in 4 (5%), 57 (73%), and 8 (10%) of patients; respectively. Three patients (4%) had neurologic events without CRS. The onset of neurologic events can be concurrent with CRS, following resolution of CRS or in the absence of CRS.

The most common neurologic events (>10%) were similar in MCL and ALL and included encephalopathy (57%), headache (37%), tremor (34%), confusional state (26%), aphasia (23%), delirium (17%), dizziness (15%), anxiety (14%), and agitation (12%). Serious events including encephalopathy, aphasia, confusional state, and seizures occurred after treatment with Tecartus.

Monitor patients daily for at least seven days for patients with MCL and at least 14 days for patients with ALL at the certified healthcare facility and for four weeks following infusion for signs and symptoms of neurologic toxicities and treat promptly.

REMS Program: Because of the risk of CRS and neurologic toxicities, Tecartus is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta and Tecartus REMS Program which requires that:

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO) or residual gentamicin in Tecartus.

Severe Infections: Severe or life-threatening infections occurred in patients after Tecartus infusion. Infections (all grades) occurred in 56% (46/82) of patients with MCL and 44% (34/78) of patients with ALL. Grade 3 or higher infections, including bacterial, viral, and fungal infections, occurred in 30% of patients with ALL and MCL. Tecartus should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after Tecartus infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.

Febrile neutropenia was observed in 6% of patients with MCL and 35% of patients with ALL after Tecartus infusion and may be concurrent with CRS. The febrile neutropenia in 27 (35%) of patients with ALL includes events of febrile neutropenia (11 (14%)) plus the concurrent events of fever and neutropenia (16 (21%)). In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated.

In immunosuppressed patients, life-threatening and fatal opportunistic infections have been reported. The possibility of rare infectious etiologies (e.g., fungal and viral infections such as HHV-6 and progressive multifocal leukoencephalopathy) should be considered in patients with neurologic events and appropriate diagnostic evaluations should be performed.

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.

Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and Tecartus infusion. In patients with MCL, Grade 3 or higher cytopenias not resolved by Day 30 following Tecartus infusion occurred in 55% (45/82) of patients and included thrombocytopenia (38%), neutropenia (37%), and anemia (17%). In patients with ALL who were responders to Tecartus treatment, Grade 3 or higher cytopenias not resolved by Day 30 following Tecartus infusion occurred in 20% (7/35) of the patients and included neutropenia (12%) and thrombocytopenia (12%); Grade 3 or higher cytopenias not resolved by Day 60 following Tecartus infusion occurred in 11% (4/35) of the patients and included neutropenia (9%) and thrombocytopenia (6%). Monitor blood counts after Tecartus infusion.

Hypogammaglobulinemia: B cell aplasia and hypogammaglobulinemia can occur in patients receiving treatment with Tecartus. Hypogammaglobulinemia was reported in 16% (13/82) of patients with MCL and 9% (7/78) of patients with ALL. Monitor immunoglobulin levels after treatment with Tecartus and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement.

The safety of immunization with live viral vaccines during or following Tecartus treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least six weeks prior to the start of lymphodepleting chemotherapy, during Tecartus treatment, and until immune recovery following treatment with Tecartus.

Secondary Malignancies may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.

Effects on Ability to Drive and Use Machines: Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following Tecartus infusion. Advise patients to refrain from driving and engaging in hazardous activities, such as operating heavy or potentially dangerous machinery, during this period.

Adverse Reactions: The most common non-laboratory adverse reactions ( 20%) were fever, cytokine release syndrome, hypotension, encephalopathy, tachycardia, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting. The most common serious adverse reactions ( 2%) were cytokine release syndrome, febrile neutropenia, hypotension, encephalopathy, fever, infection with pathogen unspecified, hypoxia, tachycardia, bacterial infections, respiratory failure, seizure, diarrhea, dyspnea, fungal infections, viral infections, coagulopathy, delirium, fatigue, hemophagocytic lymphohistiocytosis, musculoskeletal pain, edema, and paraparesis.

About Kite

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kites singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit http://www.kitepharma.com. Follow Kite on social media on Twitter (@KitePharma) and LinkedIn.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Tecartus; the risk that physicians may not see the benefits of prescribing Tecartus for the treatment of blood cancers; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gileads Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

U.S. Prescribing Information for Tecartus including BOXED WARNING, is available at http://www.kitepharma.com and http://www.gilead.com .

Kite, the Kite logo, Tecartus and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies .

View source version on businesswire.com: https://www.businesswire.com/news/home/20220722005258/en/

Jacquie Ross, Investors investor_relations@gilead.com

Anna Padula, Media apadula@kitepharma.com

Source: Gilead Sciences, Inc.

Read the rest here:
Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Gilead Sciences